feed,title,long_url,short_url
Benzinga,Duchenne Gene Therapy Firm Sarepta Therapeutics' Earns 8% Price Target Hike From This Analyst,https://benzinga.com/analyst-ratings/analyst-color/22/07/28271508/needham-bullish-on-this-duchenne-gene-therapys-accelerated-filing,https://bit.ly/3cPBCQK
